Correction: Differential response to α-oxoaldehydes in tamoxifen resistant MCF-7 breast cancer cells (PLoS ONE (2014) 9, 7 (e101473) DOI:10.1371/journal.pone.0101473);Differential response to α-axoaldehydes in tamoxifen resistant MCF-7 breast cancer cells

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Nass, Norbert ^a   Brömme, Hans Jürgen ^b   Hartig, Roland ^a   Korkmaz, Sevil ^c   Sel, Saadettin ^c   Hirche, Frank ^b   Ward, Aoife ^d   Simm, Andreas ^b   Wiemann, Stefan ^d   Lykkesfeldt, Anne E ^e   Roessner, Albert ^a   Kalinski, Thomas ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDEHYDE DERIVATIVE; ALPHA AXOALDEHYDE DERIVATIVE; CASPASE; ESTROGEN RECEPTOR; FRUCTOSAMINE 3 KINASE; GLUTATHIONE; GLYOXAL; GLYOXALASE; GLYOXALASE 1; GLYOXALASE 2; I KAPPA B ALPHA; MESSENGER RNA; METHYLGLYOXAL; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOTRANSFERASE; REACTIVE OXYGEN METABOLITE; TAMOXIFEN; THIOL GROUP; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; FRUCTOSAMINE-3-KINASE; I KAPPA B KINASE; TUMOR PROTEIN;

ARTICLE; BIOACCUMULATION; BREAST CARCINOMA; CANCER RESISTANCE; CARCINOMA CELL; CELL VIABILITY; CHEMICAL STRESS; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; HUMAN CELL; MCF 7 CELL LINE; NUCLEOTIDE SEQUENCE; SIGNAL TRANSDUCTION; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; I-KAPPA B KINASE; NEOPLASM PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PYRUVALDEHYDE; TAMOXIFEN;

EID: 84903594884     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104322     Document Type: Erratum

References (57)

1. Clemons M, Danson S, Howell A (2002) Tamoxifen ("Nolvadex"): a review. Cancer Treat Rev 28: 165-180.
2. Kurebayashi J (2005) Resistance to endocrine therapy in breast cancer. Cancer Chemother Pharmacol 56 Suppl 1: 39-46.
3. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JMW, et al. (2003) Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144: 1032-1044. (Pubitemid 36262870)
4. Vienonen A, Miettinen S, Manninen T, Altucci L, Wilhelm E, et al. (2003) Regulation of nuclear receptor and cofactor expression in breast cancer cell lines. Eur J Endocrinol 148: 469-479. (Pubitemid 36527419)
5. Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, et al. (2007) Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 7: 59.
6. Ward A, Balwierz A, Zhang JD, Küblbeck M, Pawitan Y, et al. (2013) Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene. 32(9):1173-82.
7. Ignatov A, Ignatov T, Weissenborn C, Eggemann H, Bischoff J, et al. (2011) G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Breast Cancer Res Treat 128: 457-466.
8. Ignatov A, Ignatov T, Roessner A, Costa SD, Kalinski T (2010) Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Res Treat 123: 87-96.
9. Upadhyay M, Samal J, Kandpal M, Singh OV, Vivekanandan P (2012) The Warburg effect: Insights from the past decade. Pharmacol Ther. 137(3):318-30
10. Thornalley PJ, Rabbani N (2011) Glyoxalase in tumourigenesis and multidrug resistance. Semin Cell Dev Biol 22: 318-325.
11. Nass N, Bartling B, Navarrete Santos A, Scheubel RJ, Börgermann J, et al. (2007) Advanced glycation end products, diabetes and ageing. Z Gerontol Geriatr 40: 349-356.
12. Glomb MA, Pfahler C (2001) Amides are novel protein modifications formed by physiological sugars. J Biol Chem 276: 41638-41647.
13. Sato T, Iwaki M, Shimogaito N, Wu X, Yamagishi S-I, et al. (2006) TAGE (toxic AGEs) theory in diabetic complications. Curr Mol Med 6: 351-358.
14. Cai W, He JC, Zhu L, Chen X, Zheng F, et al. (2008) Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am J Pathol 173: 327-336.
15. Ahmed N, Dobler D, Dean M, Thornalley PJ (2005) Peptide mapping identifies hotspot site of modification in human serum albumin by methylglyoxal involved in ligand binding and esterase activity. J Biol Chem 280: 5724-5732. (Pubitemid 40280052)
16. Hunter SJ, Boyd AC, O'Harte FPM, McKillop AM, Wiggam MI, et al. (2003) Demonstration of glycated insulin in human diabetic plasma and decreased biological activity assessed by euglycemic-hyperinsulinemic clamp technique in humans. Diabetes 52: 492-498. (Pubitemid 36173208)
17. Bansode SB, Chougale AD, Joshi RS, Giri AP, Bodhankar SL, et al. (2013) Proteomic analysis of protease resistant proteins in the diabetic rat kidney. Mol Cell Proteomics 12: 228-236.
18. Van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, et al. (2008) Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117: 43-51. (Pubitemid 350291180)
19. Bierhaus A, Fleming T, Stoyanov S, Leffler A, Babes A, et al. (2012) Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med 18: 926-933.
20. Nass N, Vogel K, Hofmann B, Presek P, Silber R-E, et al. (2010) Glycation of PDGF results in decreased biological activity. Int J Biochem Cell Biol 42: 749-754.
21. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, et al. (2005) Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83: 876-886. (Pubitemid 41598688)
22. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, et al. (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267: 14998-15004.
23. Rabbani N, Thornalley PJ (2012) Methylglyoxal, glyoxalase 1 and the dicarbonyl proteome. Amino Acids 42: 1133-1142.
24. Veiga da-Cunha M, Jacquemin P, Delpierre G, Godfraind C, Théate I, et al. (2006) Increased protein glycation in fructosamine 3-kinase-deficient mice. Biochem J 399: 257-264. (Pubitemid 44570288)
25. Vivacqua A, Lappano R, De Marco P, Sisci D, Aquila S, et al. (2009) G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells. Mol Endocrinol 23: 1815-1826.
26. Roepke TA, Qiu J, Bosch MA, Rønnekleiv OK, Kelly MJ (2009) Cross-talk between membrane-initiated and nuclear-initiated oestrogen signalling in the hypothalamus. J Neuroendocrinol 21: 263-270.
27. Pilkis SJ, Granner DK (1992) Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu Rev Physiol 54: 885-909.
28. Thrane S, Lykkesfeldt AE, Larsen MS, Sorensen BS, Yde CW (2013) Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. Breast Cancer Res Treat 139: 71-80.
29. Schleicher ED, Wagner E, Nerlich AG (1997) Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 99: 457-468. (Pubitemid 27414803)
30. Oya T, Hattori N, Mizuno Y, Miyata S, Maeda S, et al. (1999) Methylglyoxal modification of protein. Chemical and immunochemical characterization of methylglyoxal-arginine adducts. J Biol Chem 274: 18492-18502.
31. Pourmotabbed T, Creighton DJ (1986) Substrate specificity of bovine liver formaldehyde dehydrogenase. J Biol Chem 261: 14240-14244. (Pubitemid 17196333)
32. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Meth 9: 671-675.
33. (0) cells without a functional respiratory chain. Biol Chem 390: 915-919.
34. Weiner LM, Hu H, Swartz HM (1991) EPR method for the measurement of cellular sulfhydryl groups. FEBS Lett 290: 243-246.
35. Jänicke RU, Sprengart ML, Wati MR, Porter AG (1998) Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273: 9357-9360. (Pubitemid 28183012)
36. Rabbani N, Xue M, Thornalley PJ (2014) Activity, regulation, copy number and function in the glyoxalase system. Biochem Soc Trans 42: 419-424.
37. Toyokuni S, Okamoto K, Yodoi J, Hiai H (1995) Persistent oxidative stress in cancer. FEBS Letters 358: 1-3.
38. Creighton DJ, Zheng Z-B, Holewinski R, Hamilton DS, Eiseman JL (2003) Glyoxalase I inhibitors in cancer chemotherapy. Biochem Soc Trans 31: 1378-1382. (Pubitemid 38030980)
39. Jiang Q, Zheng S, Wang G (2013) Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancer. Future Med Chem 5: 1023-1035.
40. Droog M, Beelen K, Linn S, Zwart W (2013) Tamoxifen resistance: From bench to bedside. Eur J Pharmacol. 717(1-3):47-57
41. Santen RJ, Fan P, Zhang Z, Bao Y, Song RX-D, et al. (2009) Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells. Steroids 74: 586-594.
42. Fukunaga M, Miyata S, Liu BF, Miyazaki H, Hirota Y, et al. (2004) Methylglyoxal induces apoptosis through activation of p38 MAPK in rat Schwann cells. Biochem Biophys Res Commun 320: 689-695. (Pubitemid 38887199)
43. Kuntz S, Kunz C, Rudloff S (2010) Carbonyl compounds methylglyoxal and glyoxal affect interleukin-8 secretion in intestinal cells by superoxide anion generation and activation of MAPK p38. Mol Nutr Food Res 54: 1458-1467.
44. Liu B-F, Miyata S, Hirota Y, Higo S, Miyazaki H, et al. (2003) Methylglyoxal induces apoptosis through activation of p38 mitogen-activated protein kinase in rat mesangial cells. Kidney Int 63: 947-957. (Pubitemid 36315572)
45. Du J, Cai S, Suzuki H, Akhand AA, Ma X, et al. (2003) Involvement of MEKK1/ERK/P21Waf1/Cip1 signal transduction pathway in inhibition of IGF-I-mediated cell growth response by methylglyoxal. J Cell Biochem 88: 1235-1246. (Pubitemid 36397461)
46. Chan W-H, Wu H-J, Shiao N-H (2007) Apoptotic signaling in methylglyoxal-treated human osteoblasts involves oxidative stress, c-Jun N-terminal kinase, caspase-3, and p21-activated kinase 2. Journal of Cellular Biochemistry 100: 1056-1069.
47. Akhand AA, Kato M, Suzuki H, Liu W, Du J, et al. (1999) Carbonyl compounds cross-link cellular proteins and activate protein-tyrosine kinase p60c-Src. J Cell Biochem 72: 1-7.
48. Chang T, Wang R, Olson DJH, Mousseau DD, Ross ARS, et al. (2011) Modification of Akt1 by methylglyoxal promotes the proliferation of vascular smooth muscle cells. FASEB J 25: 1746-1757.
49. Jia X, Chang T, Wilson TW, Wu L (2012) Methylglyoxal mediates adipocyte proliferation by increasing phosphorylation of Akt1. PLoS ONE 7: e36610.
50. Akhand AA, Hossain K, Mitsui H, Kato M, Miyata T, et al. (2001) Glyoxal and methylglyoxal trigger distinct signals for map family kinases and caspase activation in human endothelial cells. Free Radic Biol Med 31: 20-30. (Pubitemid 32568420)
51. Thornalley PJ, Yurek-George A, Argirov OK (2000) Kinetics and mechanism of the reaction of aminoguanidine with the α-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. Biochemical Pharmacology 60: 55-65. (Pubitemid 30243085)
52. Lykkesfeldt AE, Madsen MW, Briand P (1994) Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res 54: 1587-1595.
53. Bachmeier BE, Nerlich AG, Rohrbach H, Schleicher ED, Friess U (2008) Maillard products as biomarkers in cancer. Ann N Y Acad Sci 1126: 283-287. (Pubitemid 351589319)
54. Fonseca-Sánchez MA, Rodríguez Cuevas S, Mendoza-Hernández G, Bautista-Piña V, Arechaga Ocampo E, et al. (2012) Breast cancer proteomics reveals a positive correlation between glyoxalase 1 expression and high tumor grade. Int J Oncol 41: 670-680.
55. Germanová A, Germanová A, Tesarová P, Jáchymová M, Zvára K, et al. (2009) Glyoxalase I Glu111Ala polymorphism in patients with breast cancer. Cancer Invest 27: 655-660.
56. Sakamoto H, Mashima T, Sato S, Hashimoto Y, Yamori T, et al. (2001) Selective activation of apoptosis program by S-p-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells. Clin Cancer Res 7: 2513-2518. (Pubitemid 32751657)
57. Ghosh M, Talukdar D, Ghosh S, Bhattacharyya N, Ray M, et al. (2006) In vivo assessment of toxicity and pharmacokinetics of methylglyoxal. Augmentation of the curative effect of methylglyoxal on cancer-bearing mice by ascorbic acid and creatine. Toxicol Appl Pharmacol 212: 45-58.